Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).

Trial Details

NCT ID

NCT05447702

Phase

PHASE2

Sponsor

West China Hospital

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

Camrelizumab
Apatinib
Nab-paclitaxel
Epirubicin
Cyclophosphamide

Locations (sample)

Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

Newly diagnosed breast cancer.
18-75 Years, female.
Early or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression).
Tumor stage: II-III.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →